跳轉至內容
Merck
全部照片(1)

文件

R2530

Sigma-Aldrich

罗匹尼罗 盐酸盐

powder, ≥98% (HPLC)

同義詞:

4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one hydrochloride, SKF 101468 hydrochloride

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C16H24N2O · HCl
CAS號碼:
分子量::
296.84
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

light yellow

溶解度

H2O: >10 mg/mL

起源

GlaxoSmithKline

SMILES 字串

Cl.CCCN(CCC)CCc1cccc2NC(=O)Cc12

InChI

1S/C16H24N2O.ClH/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15;/h5-7H,3-4,8-12H2,1-2H3,(H,17,19);1H

InChI 密鑰

XDXHAEQXIBQUEZ-UHFFFAOYSA-N

基因資訊

尋找類似的產品? 前往 產品比較指南

生化/生理作用

An agonist at the D2 and D3 dopamine receptor subtypes, binding with higher affinity to D3 than to D2 or D4. It has negligible effect on D1-receptors. It has medium in vitro affinity to opioid receptors. Ropinirole is said to have virtually no affinity to 5-HT1, 5-HT2, benzodiazepine, GABA, muscarinic, α1-, α2-, and β-adrenoreceptors. Used as antiparkinsonian drug.
Ropinirole hydrochloride is effectively used to treat early and late Parkinson′s disease.

特點和優勢

This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形圖

Exclamation markEnvironment

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral - Aquatic Acute 1

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Francisco J Zagmutt et al.
The International journal of neuroscience, 122(7), 345-353 (2012-02-07)
The comparative safety profiles of monotherapeutic treatments for Parkinson's disease (PD) can provide valuable therapeutic information. The objective of this study was to perform an indirect comparison of Adverse Events (AEs) and Dropout Rates (DRs) among clinical trials of pramipexole
Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome.
Benjamin J Dorfman et al.
Parkinsonism & related disorders, 19(2), 269-270 (2012-07-04)
N Hattori et al.
Journal of clinical pharmacy and therapeutics, 37(5), 571-577 (2012-03-07)
Ropinirole hydrochloride, a dopamine receptor agonist with a non-ergot alkaloid structure, is highly selective for the dopamine D(2) /D(3) receptors. This study was conducted to evaluate the steady-state pharmacokinetics, safety and efficacy after repeated oral administration of prolonged-release tablets of
T Nissen et al.
Scottish medical journal, 57(4), 217-220 (2012-09-25)
The expected duration of initial antiparkinson monotherapy before the need for supplementation is not clearly defined for routine practice. The aim of this study was to define the length of L-dopa (L-3, 4-dihydrophenylalanine) and dopamine agonist monotherapy. The duration of
Sébastien Duband et al.
Journal of forensic and legal medicine, 19(7), 422-425 (2012-08-28)
Ropinirole, a specific non-ergoline dopamine D2-receptor agonist, belongs to the drugs applied in treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) and acts as a D2, D3, and D4 dopamine receptor agonist with highest affinity for D3. Therapeutic

文章

We offer many products related to dopamine receptors for your research needs.

我們提供許多與多巴胺受體相關的產品,以滿足您的研究需求。

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務